Latest news with #IHHHealthcareBhd
The Star
6 days ago
- Business
- The Star
IHH revenue grows to RM6.29bil in 1Q25
PETALING JAYA: IHH Healthcare Bhd will be forging ahead with its expansion and growth strategies to meet the increasing demand for quality healthcare services locally and across the region. Following the acquisitions of Timberland Medical Centre in Sarawak and Island Hospital in Penang in 2024, the group said in a Bursa Malaysia filing that it had opened the 127-bed Acibadem Kartal Hospital in Turkiye in the first quarter ended March 31, 2025 (1Q25) and expects to complete the acquisition of the 228-bedded Shrimann Superspeciality Hospital in India during the year. For 1Q25, IHH's net profit dropped to RM514mil from RM768mil in the previous corresponding quarter, while revenue grew to RM6.29bil from RM5.96bil a year earlier. 'The growth in revenue was driven by a sustained demand for quality healthcare services, a case-mix of more acute patients and price adjustments to counter inflation. 'The consolidation of Island Hospital, which was acquired in November 2024, also contributed to the increase in revenue.' IHH said its Singapore hospital inpatient admissions decreased 6% to 14,493 in 1Q25 while its revenue per inpatient admission increased 10% to RM67,294. 'Malaysia's hospital inpatient admissions increased 6% at 62,406 in 1Q25 while its revenue per inpatient admission increased 6% to RM11,334. 'India's hospital inpatient admissions increased 7% to 78,485 in 1Q25 while its revenue per inpatient admission increased 4% to RM10,152.' Meanwhile, Turkiye and Europe hospital inpatient admissions was flat at 66,776 in 1Q25 while its revenue per inpatient admission increased 16% to RM13,522 with price adjustments, especially in Turkiye, to counter hyperinflation. While the demand for quality healthcare remains robust, IHH said ongoing industry-wide challenges including rising cost pressures as well as higher energy costs and staff costs. 'In addition, payor pressures from both public and private insurers continue to shape reimbursement dynamics in the industry.' To unlock value from its key markets and to address the industry-wide challenges, IHH said it has embarked on a multi-year transformation initiative to drive continuous improvement through seven focus areas. The areas are clinical excellence, patient experience, new care models, operational excellence, payor and regulator engagement, employee and doctor value proposition, and the advancement of technology, data, and artificial intelligence. 'The group remains in a good position given its strong track record in delivering high-quality and cost-effective healthcare. 'By leveraging operational synergies across its international network, the group remains confident in its ability to maintain cost efficiency while upholding its commitment to value-based healthcare.' Despite global economic and geopolitical headwinds, IHH said it remains well-poised to navigate uncertainties, underpinned by strong fundamentals, strategic growth initiatives, and long-term healthcare megatrends.
New Straits Times
7 days ago
- Business
- New Straits Times
IHH healthcare Q1 net profit falls to RM514mil
KUALA LUMPUR: IHH Healthcare Bhd has recorded a drop in net profit to RM514 million in the first quarter of its financial year ending Dec 31, 2025 (1Q FY2025) from RM768 million in 1Q FY2024. Revenue for the quarter under review rose to RM6.29 billion from RM5.96 billion last year, due to gains in the hospital and healthcare segments and Parkway Life REIT (PLife REIT), the company said in a filing with Bursa Malaysia. "Hospital and healthcare revenue in 1Q FY2025 increased by 7.0 per cent to RM6.05 billion, driven by sustained demand for quality healthcare services, a case-mix of more acute patients, and price adjustments to counter inflation. "The consolidation of Island Hospital, which was acquired in November 2024, also contributed to the increase in revenue," it said. IHH Healthcare added that PLife REIT's external revenue for 1Q FY2025 rose 15 per cent to RM45 million, driven by contributions from the 11 nursing home properties in France acquired in December 2024. The company remains in a strong position, given its track record in delivering high-quality and cost-effective healthcare. By leveraging operational synergies across its international network, IHH Healthcare remains confident in its ability to maintain cost efficiency while upholding its commitment to value-based healthcare. "Despite global economic and geopolitical headwinds, the group remains well poised to navigate uncertainties, underpinned by strong fundamentals, strategic growth initiatives, and long-term healthcare megatrends," it said
The Star
7 days ago
- Business
- The Star
IHH to forge ahead with expansion and growth strategies
PETALING JAYA: IHH Healthcare Bhd will be forging ahead with its expansion and growth strategies to meet the increasing demand for quality healthcare services locally and across the region. Following the acquisitions of Timberland Medical Centre in Sarawak and Island Hospital in Penang in 2024, the group said in a Bursa Malaysia filing that it had opened the 127-bed Acibadem Kartal Hospital in Turkey in the first quarter of 2025 (1Q25) and expects to complete the acquisition of the 228-bedded Shrimann Superspeciality Hospital in India during the year. For 1Q25 (ended March 31, 2025), IHH's net profit dropped to RM514mil from RM768mil in the previous corresponding quarter, while revenue grew to RM6.29bil from RM5.96bil a year earlier. 'The growth in revenue was driven by a sustained demand for quality healthcare services, a case-mix of more acute patients and price adjustments to counter inflation. 'The consolidation of Island Hospital, which was acquired in November 2024, also contributed to the increase in revenue.' IHH said its Singapore hospital inpatient admissions decreased 6% to 14,493 in Q15 while its revenue per inpatient admission increased 10% to RM67,294. 'Malaysia's hospital inpatient admissions increased 6% at 62,406 in 1Q25 while its revenue per inpatient admission increased 6% to RM11,334. 'India's hospital inpatient admissions increased 7% to 78,485 in 1Q25 while its revenue per inpatient admission increased 4% to RM10,152.' Meanwhile, Turkiye and Europe hospital inpatient admissions was flat at 66,776 in 1Q25 while its revenue per inpatient admission increased 16% to RM13,522 with price adjustments, especially in Turkiye, to counter hyperinflation. While the demand for quality healthcare remains robust, IHH said ongoing industry-wide challenges including rising cost pressures as well as higher energy costs and staff costs. 'In addition, payor pressures from both public and private insurers continue to shape reimbursement dynamics in the industry.' To unlock value from its key markets and to address the industry-wide challenges, IHH said it has embarked on a multi-year transformation initiative to drive continuous improvement through seven focus areas - clinical excellence, patient experience, new care models, operational excellence, payor and regulator engagement, employee and doctor value proposition, and the advancement of technology, data, and artificial intelligence. 'The group remains in a good position given its strong track record in delivering high-quality and cost-effective healthcare. 'By leveraging operational synergies across its international network, the group remains confident in its ability to maintain cost efficiency while upholding its commitment to value-based healthcare.' Despite global economic and geopolitical headwinds, IHH said it remains well-poised to navigate uncertainties, underpinned by strong fundamentals, strategic growth initiatives, and long-term healthcare megatrends.
The Sun
28-05-2025
- Business
- The Sun
IHH Healthcare in transformation and expansion mode
KUALA LUMPUR: IHH Healthcare Bhd will continue to strengthen its presence across the healthcare continuum in key markets such as Singapore and Hong Kong, expanding into the ambulatory care segment alongside its existing primary care clinics. On the inorganic growth front, the group is on the lookout for strategic acquisitions, including hospitals in Malaysia, India and Turkiye. Group CEO Dr Prem Kumar Nair said while underperforming assets in China represent only a small fraction of IHH's overall portfolio, they have recently shown signs of improvement. 'In fact, the group remains optimistic about its prospects in China and is set to invest in a major ambulatory care centre in Shanghai,' he told reporters after the company's annual general meeting today. Dr Prem said what is particularly significant at this stage is the recognition that IHH must undergo – a comprehensive transformation to achieve many of its strategic goals. 'As a well-established organisation, some of our hospitals have been serving communities for decades – Punggol East in Singapore, Gleneagles with a 65-year legacy, Mount Elizabeth approaching 50 years, as well as Gleneagles Penang and Pantai Hospital Kuala Lumpur, both with over half a century of service. 'Given this legacy, we are now shifting our focus towards key transformation areas. 'One of the most important is the introduction of a new care model, which we have already begun implementing in markets like Singapore and Hong Kong. We are also actively encouraging other countries within our network to adopt this forward-looking approach to healthcare delivery,' Dr Prem said. The group's revenue in FY24 increased 16% to RM24.4 billion, and earnings before interest, taxes, depreciation and amortisation) stood at RM5.4 billion, a 17% growth from FY23. Profit after tax and minority Interest (Patmi) declined 10% to RM2.7 billion, mainly due to the one-off gain from the disposal of the International Medical University in 2023. Excluding extraordinary items, Patmi grew 32% from a year ago to RM1.7 billion. Return-on-equity (ROE) growth remains a key focus, and on the back of the strong financial performance, IHH declared a total of 10 sen per share in ordinary dividends in FY24, an increase from 9 sen per share in FY23. 'Many have asked whether factors like tariffs and geopolitical uncertainty – including developments in Turkiye and the US presidency of Donald Trump – have had an impact on us. 'Despite these external challenges, we have demonstrated strong resilience, delivering double-digit revenue and profit growth and achieving an ROE of 9%, edging closer to our target of double-digit ROE,' Dr Prem said. He said IHH's success is defined by meeting or exceeding a comprehensive set of indicators for each value-driven care procedure. Currently, the group is tracking eight high-volume procedures under this framework – including total knee replacement, colonoscopy, and breast cancer – monitoring over 360 indicators every month. These procedures account for about 20% of all inpatient admissions across the network, representing a significant portion of patient care and clinical activity. 'By next year, we plan to expand this programme to include two additional procedures, such as Caesarean sections, allowing more patients to benefit from outcome-driven care. 'To achieve and elevate the level of quality we aim for, we are making strategic investments in cutting-edge medical equipment and improved infrastructure,' Dr Prem said. As a group, he pointed out, IHH reinvests its profits into clinical research, quality improvement programmes and innovations aimed at enhancing patient outcomes. The company has embraced technology-driven care, such as ProtonBeam therapy for cancer treatment, and is creating seamless digital experiences to elevate service quality, including through the MyHealth360 app, which gives patients direct access to their healthcare. Equally important, Dr Prem said, IHH is committed to empowering both patients and staff by investing in continuous learning, development and modern work tools to enable its people to deliver exceptional care and perform at their best.
The Sun
28-05-2025
- Business
- The Sun
IHH Healhcare in transformation and expansion mode
KUALA LUMPUR: IHH Healthcare Bhd will continue to strengthen its presence across the healthcare continuum in key markets such as Singapore and Hong Kong, expanding into the ambulatory care segment alongside its existing primary care clinics. On the inorganic growth front, the group is on the lookout for strategic acquisitions, including hospitals in Malaysia, India and Turkiye. Group CEO Dr Prem Kumar Nair said while underperforming assets in China represent only a small fraction of IHH's overall portfolio, they have recently shown signs of improvement. 'In fact, the group remains optimistic about its prospects in China and is set to invest in a major ambulatory care centre in Shanghai,' he told reporters after the company's annual general meeting yesterday. Prem said what is particularly significant at this stage is the recognition that IHH must undergo – a comprehensive transformation to achieve many of its strategic goals. 'As a well-established organisation, some of our hospitals have been serving communities for decades – Punggol East in Singapore, Gleneagles with a 65-year legacy, Mount Elizabeth approaching 50 years, as well as Gleneagles Penang and Pantai Hospital Kuala Lumpur, both with over half a century of service. 'Given this legacy, we are now shifting our focus towards key transformation areas. 'One of the most important is the introduction of a new care model, which we have already begun implementing in markets like Singapore and Hong Kong. We are also actively encouraging other countries within our network to adopt this forward-looking approach to healthcare delivery,' Prem said. The group's revenue in FY24 increased 16% to RM24.4 billion, and earnings before interest, taxes, depreciation and amortisation) stood at RM5.4 billion, a 17% growth from FY23. Profit after tax and minority Interest (Patmi) declined 10% to RM2.7 billion, mainly due to the one-off gain from the disposal of the International Medical University in 2023. Excluding extraordinary items, Patmi grew 32% from a year ago to RM1.7 billion. Return-on-equity (ROE) growth remains a key focus, and on the back of the strong financial performance, IHH declared a total of 10 sen per share in ordinary dividends in FY24, an increase from 9 sen per share in FY23. 'Many have asked whether factors like tariffs and geopolitical uncertainty – including developments in Turkiye and the US presidency of Donald Trump – have had an impact on us. 'Despite these external challenges, we have demonstrated strong resilience, delivering double-digit revenue and profit growth and achieving an ROE of 9%, edging closer to our target of double-digit ROE,' Prem said. He said IHH's success is defined by meeting or exceeding a comprehensive set of indicators for each value-driven care procedure. Currently, the group is tracking eight high-volume procedures under this framework – including total knee replacement, colonoscopy, and breast cancer – monitoring over 360 indicators every month. These procedures account for about 20% of all inpatient admissions across the network, representing a significant portion of patient care and clinical activity. 'By next year, we plan to expand this programme to include two additional procedures, such as Caesarean sections, allowing more patients to benefit from outcome-driven care. 'To achieve and elevate the level of quality we aim for, we are making strategic investments in cutting-edge medical equipment and improved infrastructure,' Prem said. As a group, he pointed out, IHH reinvests its profits into clinical research, quality improvement programmes and innovations aimed at enhancing patient outcomes. The company has embraced technology-driven care, such as ProtonBeam therapy for cancer treatment, and is creating seamless digital experiences to elevate service quality, including through the MyHealth360 app, which gives patients direct access to their healthcare. Equally important, Prem said, IHH is committed to empowering both patients and staff by investing in continuous learning, development and modern work tools to enable its people to deliver exceptional care and perform at their best.
